Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743822 | 0.81 | ADRA2A (0.43) | PDE7ACYP2C19KDM1AADRA2AAR | |
| SCHEMBL3465028 | 0.80 | PDE7A (0.49) | PDE7ACYP2C19KDM1AMEN1KMT2A | |
| SCHEMBL28465895 | 0.79 | KDM1A (0.48) | PDE7ACYP2C19KDM1AADRA2ACHRNA7 | |
| SCHEMBL3465025 | 0.78 | PDE7A (0.43) | PDE7ACYP2C19KDM1AADRA2AGAA | |
| SCHEMBL3465027 | 0.78 | PDE7A (0.43) | PDE7ACYP2C19KDM1AADRA2AGAA | |
| SCHEMBL9176801 | 0.75 | AKR1B1 (0.60) | PDE7ACYP2C19KDM1A | |
| SCHEMBL1972093 | 0.74 | TSHR (0.58) | PDE7A | |
| SCHEMBL3465309 | 0.71 | KDM1A (0.43) | PDE7ACYP2C19KDM1AADRA2A | |
| SCHEMBL3464559 | 0.71 | KDM1A (0.46) | PDE7ACYP2C19KDM1AADRA2A | |
| SCHEMBL24699351 | 0.71 | TDP2 (0.45) | KDM1APARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PDE7A 915/4885CYP2C19 49/4885KDM1A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.